MALARIA ERADICATION
THROUGH VACCINATION
Sanaria's vaccines are intended to be used to prevent malaria in individuals and, in combination with other malaria control measures, to halt transmission of and eliminate malaria from communities.
Sanaria Participates in World Malaria Day Exhibition in Washington, DC
On May 6, 2026, Sanaria was honored to attend the World Malaria Day Exhibition at the Rayburn House Office Building near the U.S. Capitol in Washington, DC. Sanaria was pleased to participate by invitation in this important event, which was organized by Malaria No More and United to Beat Malaria to raise awareness of the continued global burden of malaria and the urgent need for sustained commitment to malaria eradication. The exhibition brought together organizations and advocates dedicated to advancing the fight against malaria and highlighting the impact this disease continues to have on hundreds of millions of people worldwide. Sanaria was proud to join fellow participants in sharing the importance of innovation, collaboration, and continued investment in malaria prevention, treatment, and vaccine development. Events such as this serve as an important reminder that ending malaria will require a broad and united effort across the scientific, public health, advocacy, and policy communities. Sanaria is grateful to Malaria No More and United to Beat Malaria for the invitation to participate in this meaningful event. We remain committed to supporting global efforts to eliminate malaria and to advancing solutions that can help bring an end to one of the world’s most devastating infectious diseases.
Malaria No More Visits Sanaria
On Tuesday, May 5, 2026, Sanaria was honored to welcome William (Bill) Steiger CEO and the team from Malaria No More for a visit to our facilities. Their visit was both meaningful and inspiring for our team, providing an opportunity to engage with a group whose dedication to ending malaria continues to make a profound global impact. Throughout the visit, the Sanaria team was deeply impressed by the Malaria No More team’s knowledge, passion, and unwavering commitment to the hundreds of millions of people affected by malaria each year. Their advocacy, leadership, and sense of urgency in the fight against this devastating disease resonated strongly with all of us. It was a privilege to share perspectives, discuss the ongoing challenges in malaria prevention and treatment, and reflect on the importance of collaboration across organizations working toward the same goal. At Sanaria, our mission is rooted in the belief that malaria can and must be defeated. Visits such as this reinforce the importance of partnership, innovation, and persistence in advancing solutions that can protect vulnerable populations around the world. We are grateful to the Malaria No More team for spending time with us. We look forward to continued engagement as we all work toward a future free from malaria.
The Annual International PfSPZ Consortium Met in Toronto, Canada on November 8th & 9th, 2025
The 2025 iPfSPZ-C meeting brought together scientists from around the world to review an extraordinary year of progress in Plasmodium falciparum sporozoite (PfSPZ) vaccine and other SPZ research. Over a day and a half, 48 scientists from 11 countries presented major scientific breakthroughs, steady advances in product development, and coordinated plans for global evaluation of Sanaria’s PfSPZ-based malaria vaccines to the in-person participants and on-line participants around the world.
Sanaria Reports Positive Initial Safety Results for Groundbreaking PfSPZ-LARC2 Malaria Vaccine
Physician-scientists at Groupe de Recherche Action en Santé (GRAS) in Burkina Faso have successfully completed initial safety evaluations in 30 adult Burkinabés as the first phase of a clinical trial of Sanaria® PfSPZ-LARC2 Vaccine, which is designed to prevent infection with Plasmodium falciparum malaria.
A Single-Dose Breakthrough: PfSPZ-LARC Vaccines Offer Transformative Protection Against Malaria
Scientists at Sanaria and Seattle Children’s Research Institute’s Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, designed to provide high-level protection with just one dose. This innovative approach leverages decades of research and cutting-edge genetic engineering to combat one of the world’s deadliest diseases.
Sanaria’s CEO, Dr. Stephen L. Hoffman awarded the Walter Reed Medal at the American Society of Tropical Medicine’s Annual Conference
The Walter Reed Medal is awarded every year to recognize distinguished accomplishments in the field of tropical medicine.
An Urgent Need for Malaria Vaccines
Sanaria has an innovative approach to malaria vaccines using Plasmodium falciparum (Pf) sporozoites (SPZ) as the platform technology for immunizing people against malaria infection. The proven effective results of this approach are documented in Sanaria’s publications.
Global Collaboration: The I-PfSPZ Consortium
Semi-annually, Sanaria organizes the international PfSPZ Consortium (i-PfSPZ-C) meeting for our partners, collaborators and funders where we analyze, present and discuss our findings prior to publication. The i-PfSPZ-C allows our collaborators and partners to share their work, modify research and clinical plans based on the consortium efforts and map out future funding needs.
Subscribe
Our Malaria Vaccine Pipeline
Innovative routes to success. A major impact in global health.
